Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 9 studies | 28% ± 6% | |
endothelial cell | 9 studies | 26% ± 9% | |
oligodendrocyte | 8 studies | 28% ± 8% | |
microglial cell | 7 studies | 25% ± 8% | |
oligodendrocyte precursor cell | 7 studies | 28% ± 9% | |
fibroblast | 7 studies | 23% ± 7% | |
GABAergic neuron | 6 studies | 31% ± 11% | |
natural killer cell | 6 studies | 19% ± 4% | |
adipocyte | 6 studies | 28% ± 9% | |
macrophage | 6 studies | 24% ± 8% | |
glutamatergic neuron | 5 studies | 38% ± 14% | |
dendritic cell | 5 studies | 27% ± 9% | |
pericyte | 4 studies | 19% ± 4% | |
epithelial cell | 4 studies | 28% ± 4% | |
cardiac muscle cell | 4 studies | 27% ± 8% | |
club cell | 4 studies | 26% ± 11% | |
type I pneumocyte | 4 studies | 36% ± 15% | |
neuron | 3 studies | 30% ± 11% | |
myeloid cell | 3 studies | 17% ± 1% | |
ciliated cell | 3 studies | 30% ± 11% | |
type II pneumocyte | 3 studies | 30% ± 9% | |
basal cell | 3 studies | 29% ± 10% | |
transit amplifying cell | 3 studies | 23% ± 6% | |
T cell | 3 studies | 31% ± 13% | |
endothelial cell of lymphatic vessel | 3 studies | 29% ± 11% | |
interneuron | 3 studies | 35% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2730.60 | 1445 / 1445 | 100% | 50.11 | 183 / 183 |
lung | 100% | 2974.58 | 578 / 578 | 100% | 63.43 | 1155 / 1155 |
ovary | 100% | 2483.57 | 180 / 180 | 100% | 58.67 | 430 / 430 |
prostate | 100% | 2700.94 | 245 / 245 | 100% | 42.62 | 502 / 502 |
stomach | 100% | 2193.65 | 359 / 359 | 100% | 49.10 | 286 / 286 |
breast | 100% | 2931.18 | 459 / 459 | 100% | 63.15 | 1117 / 1118 |
brain | 100% | 1731.35 | 2638 / 2642 | 100% | 51.97 | 705 / 705 |
intestine | 100% | 2821.43 | 966 / 966 | 100% | 53.95 | 526 / 527 |
skin | 100% | 3099.05 | 1809 / 1809 | 100% | 54.46 | 471 / 472 |
uterus | 100% | 2941.56 | 170 / 170 | 100% | 61.58 | 458 / 459 |
thymus | 100% | 2787.28 | 653 / 653 | 100% | 48.31 | 603 / 605 |
bladder | 100% | 3110.90 | 21 / 21 | 100% | 54.88 | 502 / 504 |
kidney | 100% | 2248.13 | 89 / 89 | 99% | 28.38 | 892 / 901 |
pancreas | 100% | 1247.37 | 327 / 328 | 99% | 38.17 | 176 / 178 |
liver | 100% | 1189.55 | 226 / 226 | 98% | 25.25 | 398 / 406 |
adrenal gland | 100% | 2129.48 | 258 / 258 | 97% | 29.74 | 223 / 230 |
adipose | 100% | 2888.37 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2824.31 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 35.62 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 55.68 | 29 / 29 |
muscle | 100% | 3752.15 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2710.61 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 61.96 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.17 | 1 / 1 |
peripheral blood | 99% | 2316.98 | 918 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 1832.72 | 850 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0000245 | Biological process | spliceosomal complex assembly |
GO_0008380 | Biological process | RNA splicing |
GO_0006397 | Biological process | mRNA processing |
GO_0051301 | Biological process | cell division |
GO_0046540 | Cellular component | U4/U6 x U5 tri-snRNP complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | USP39 |
Protein name | Ubiquitin specific peptidase 39, isoform CRA_b (cDNA FLJ31772 fis, clone NT2RI2008007, highly similar to U4/U6.U5 tri-snRNP-associated protein 2) Ubiquitin carboxyl-terminal hydrolase 39 (EC 3.4.19.12) (SAD1 homolog) (U4/U6.U5 tri-snRNP-associated 65 kDa protein) Ubiquitin specific peptidase 39 ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
Synonyms | HSPC332 PRO2855 hCG_34614 CGI-21 |
Description | FUNCTION: Deubiquitinating enzyme that plays a role in many cellular processes including cellular antiviral response, epithelial morphogenesis, DNA repair or B-cell development . Plays a role in pre-mRNA splicing as a component of the U4/U6-U5 tri-snRNP, one of the building blocks of the precatalytic spliceosome . Specifically regulates immunoglobulin gene rearrangement in a spliceosome-dependent manner, which involves modulating chromatin interactions at the Igh locus and therefore plays an essential role in B-cell development (By similarity). Regulates AURKB mRNA levels, and thereby plays a role in cytokinesis and in the spindle checkpoint . Regulates apoptosis and G2/M cell cycle checkpoint in response to DNA damage by deubiquitinating and stabilizing CHK2 . Plays also an important role in DNA repair by controlling the recruitment of XRCC4/LIG4 to DNA double-strand breaks for non-homologous end-joining repair . Participates in antiviral activity by affecting the type I IFN signaling by stabilizing STAT1 and decreasing its 'Lys-6'-linked ubiquitination . Contributes to non-canonical Wnt signaling during epidermal differentiation (By similarity). Acts as a negative regulator NF-kappa-B activation through deubiquitination of 'Lys-48'-linked ubiquitination of NFKBIA . . |
Accessions | Q53GS9 ENST00000467885.6 ENST00000613444.4 ENST00000323701.11 [Q53GS9-1] A0A087WW31 ENST00000458268.5 ENST00000409470.5 [Q53GS9-1] B9A018 ENST00000409025.5 A0A087X1B2 B3KPG7 ENST00000450066.6 [Q53GS9-2] C9J0X5 F8WC91 C9JIU2 ENST00000448971.5 ENST00000442708.5 ENST00000409766.7 [Q53GS9-3] |